46 results about "Granulocyte colony-stimulating factor" patented technology

The present invention provides a combination epigenetic factors and bispecific compounds targeting CD33 and CD3 in the treatment of myeloid leukemia, wherein the epigenetic factor is selected from thegroup consisting of histone deacetylase (HDAC) inhibitors, DNA methyltransferase (DNMT) I inhibitors,hydroxyurea, Granulocyte-Colony Stimulating Factor (G-CSF), histone demethylase inhibitors and ATRA (All Trans-retinoic acid). Accordingly, the invention provides a pharmaceutical composition comprising a CD33 targeting compound and at least one epigenetic factor and an epigenetic factor for use in the amelioration and / or treatment of a myeloid leukemia, wherein the epigenetic factor increases the responsiveness of a patient to a CD33 targeting compound. Moreover, the invention provides the use of at least one an epigenetic factor for increasing the responsiveness of a myeloid leukemia patient to a treatment with a CD33 targeting compound, a method for the treatment of a myeloid leukemia,the method comprising the administration of at least one epigenetic factor and a CD33 targeting compound to a patient in the need thereof and a kit comprising a pharmaceutical composition of the invention or an epigenetic factor of the invention and a bispecific CD33 targeting compound.

A hematopoetic factor called “colony stimulating factor” (CSF) is capable of synergizing the attracting capabilities of chemokines and of inducing the accumulation and / or activation in vitro and in vivo of key components of inflammatory responses. Various types of agents that inhibit or otherwise hinder the production, release or activity of CSF could be used therapeutically in the treatment of ischemia and other inflammatory diseases, such as autoimmune disease, and various chronic inflammatory diseases such as rheumatoid arthritis and psoriasis.

The invention discloses a medical preparation containing a recombinant human recombination granulocytecolony stimulating factor (G-CSF) with the same structure as a natural human granulocytecolony stimulating factor and a preparation method thereof. The active ingredient of the preparation is G-CST with proline at the N terminal, is 173-numbered amino acids and is one of the natural structures of G-CST in human body. The preparation overcomes the defect that the N terminal of the existing recombinant human G-CSF product contains methionine. The invention also provides the method for preparing the preparation.

The invention relates to the field of bio-pharmaceuticals, and in particular relates to a method for preparing recombinant human granulocyte colony stimulating factors screened by microorganisms. The preparation method comprises the following steps of: selecting engineering bacteria of the recombinant human granulocyte colony stimulating factors to ferment and culture; ultrasonically pulverizing bacteria bodies obtained by fermentation medium; collecting inclusion bodies; washing the inclusion bodies with inclusion body washing solution and centrifuging at a low temperature; adding inclusion body dissolution liquid into the inclusion bodies, standing for 8-12 hours at 4 DEG C and centrifuging to obtain inclusion body extraction liquid; separating the extraction liquid by using a Sephacry1S-200 gel column; collecting a plurality of recombinant human granulocyte colony stimulating factor fractions; and separating by using a SephadexG25 column to obtain the recombinant human granulocyte colony stimulating factor. The invention also relates to a medicament composition and a preparation of the recombinant human granulocyte colony stimulating factors.

The invention relates to a method for preparing a coating carrier system for vitiligo melanocyte transplantation. , epinephrine and vitamin C mixed solution, pentamycin to configure melanocyte culture medium for the in vitro culture of autologous melanocytes, and use Carbomer gel and the above melanocyte culture medium to form a coating Cloth carrier system. The present invention uses the melanocyte culture medium containing human granulocyte colony-stimulating factor G-CSF to make the melanocyte proliferate in large quantities in vitro; The problem of easy loss of cell suspension during cell transplantation can reduce the loss of melanocytes, increase the implantation rate without causing damage to melanocytes, and reduce the cost of surgery. Treatment offers new avenues.

The invention provides a PEGylated recombinant human granulocyte colony stimulating factor (PEG-rhG-CSF) freeze-dried preparation. The PEG-rhG-CSF and an excipient are subjected to spray freeze-drying treatment, when the prepared PEG-rhG-CSF freeze-dried preparation is clinically used, a special solvent containing sodium chloride and acetate is prepared, and the freeze-dried preparation can be used after being mixed and dissolved with the special solvent. The PEG-rhG-CSF freeze-dried preparation prepared by the invention does not contain a surfactant namely Tween 20, is high in medication safety and good in stability, can be stored for a long time, and is simple in preparation process and short in production period.

This disclosure provides a method of preventing, alleviating, or treating a condition (i.e., neutropenia) in a patient in need thereof, the condition characterized by compromised white blood cell production in the patient. The method includes administering to the patient a therapeutically effective amount of a protein complex comprising a modified human granulocyte-colony stimulating factor (hG-CSF) covalently linked to an immunoglobulin Fc region via a non-peptidyl polymer. The non-peptidyl polymer is site-specifically linked to an N-terminus of the immunoglobulin Fc region, and the modified hG-CSF comprises substitutions in at least one of Cys17 and Pro65.

The invention relates to derivatives of recombinant proteins, comprising homo-multimers of genetically fused recombinant biologically active protein monomer units, connected via selected peptide linker moiety; and the method of preparation thereof. Derivative of recombinant protein is preferably dimer of human granulocyte colony-stimulating factor, characterised by increased circulation time in vivo.

The invention discloses liquid medicine for a stent, a medicine eluting stent and a preparation method of the medicine eluting stent, and relates to the technical field of elution stents. The liquid medicine for the stent comprises the following components in percentage by weight: 0.01 to 0.4 percent of granulocyte colony stimulating factor, 0.5 to 1.7 percent of rapamycin, 0.7 to 4.0 percent of polylactic acid and the balance of organic solvent. The liquid medicine for the scaffold can be combined with specific receptors on the surfaces of granulocyte progenitor cells and mature neutrophils through reasonable proportioning of granulocyte colony stimulating factors G-CSF, rapamycin, polylactic acid and acetone, promotes proliferation and differentiation of the granulocyte progenitor cells and the mature neutrophils, enhances the functions of the mature neutrophils, can promote proliferation, differentiation and maturation of medullary hematopoietic progenitor cells, and can adjust proliferation and differentiation maturation of the neutrophil line; the neutrophile granulocytes can be driven to be released to the blood flow, so that the number of peripheral neutrophile granulocytes is increased; EPCs can be mobilized to enter peripheral blood, injured vascular endothelium repair is accelerated, vascular inflammation can be reduced, and ISR can be effectively controlled.

The invention provides a method for preparing autologous hematopoietic stem cells. The method includes following steps of cultivating somatic cells in a cell culture fluid for 3-6 days and collecting the generated autologous hematopoietic stem cells. The cell culture fluid is an RPMI1640 culture fluid containing: 1-100 [mu]M of Y-27632 (C14H21N3O.2HCl), 1-100 ng / ml of stem cell factors, 1-100 ng / ml of interleukin 3, 1-100 ng / ml of interleukin 6, 1-100 ng / ml of interleukin 11, 1-100 ng / ml of a macrophage colony stimulating factor (M-CSF), 1-100 ng / ml of a granulocyte colony-stimulating factor (G-CSF), 1-100 [mu]g / ml of fucoidin, 1-100 [mu]g / ml of dextran sulfate, 1-100 nM of AMD3100 (1,1'-[1,4-phenylenebis(methylene)]-bis-1,4,8,11-tetrazacyclotetradecane), 1-100 [mu]M of M-alendronate sodium (Malendronate sodium trihydrate), and 1-100 [mu]M of disodium pamidronate. The invention provides a method for preparing the autologous hematopoietic stem cells, a kit, the stem cells and an application. In addition, the method is advantaged in yield, purity, and producing speed of the production of the protein-induced autologous hematopoietic stem cells.